Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

X-linked immunodeficiencies.

Hans D Ochs1, Luigi D Notarangelo

  • 1Department of Pediatrics, University of Washington, Children's Hospital and Regional Medical Center, 4800 Sand Point Way NE, Seattle, WA 98105, USA. allgau@u.washington.edu

Current Allergy and Asthma Reports
|July 31, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation.

Nature immunology·2026
Same author

Revisiting X-linked agammaglobulinemia.

Journal of human immunity·2026
Same author

FDA approves gene therapy for Wiskott-Aldrich syndrome.

The Journal of allergy and clinical immunology·2026
Same author

Treatment of canine hemophilia A via intraosseous delivery of a platelet-specific factor VIII-lentiviral vector.

Blood vessels, thrombosis & hemostasis·2026
Same author

Clinical spectrum of Wiskott-Aldrich syndrome carriers: Self-reported survey of 193 carriers.

Clinical immunology (Orlando, Fla.)·2025
Same author

Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.

Blood advances·2025
Same journal

Harnessing Machine Learning and Electronic Health Record Data to Improve Asthma Management.

Current allergy and asthma reports·2026
Same journal

Incorporating New Guidelines into School-Based Asthma Management.

Current allergy and asthma reports·2026
Same journal

The Modern Environment and Childhood Asthma: The Role of Air Pollution and Heavy Metal Exposure.

Current allergy and asthma reports·2026
Same journal

Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies.

Current allergy and asthma reports·2026
Same journal

The Role of the Indoor Exposome in Food Allergy Development.

Current allergy and asthma reports·2026
Same journal

Understanding Infantile Atopic Dermatitis: A Review of Environmental, Familial, Genetic and Microbial Influences.

Current allergy and asthma reports·2026
See all related articles

Molecular genetics advances have identified genes for X-linked immunodeficiencies, improving diagnostics and understanding. Gene therapy for X-linked severe combined immune deficiency shows promise but carries risks.

Area of Science:

  • Immunology
  • Molecular Genetics
  • Medical Genetics

Background:

  • X-linked immunodeficiencies (XLIDs) are a group of genetic disorders affecting the immune system.
  • Recent molecular genetics research has identified multiple genes responsible for XLIDs.
  • Understanding the genetic basis of XLIDs is crucial for diagnosis and treatment.

Purpose of the Study:

  • To review recent advances in the molecular genetics of X-linked immunodeficiencies.
  • To highlight the impact of genetic discoveries on diagnosis, pathophysiology, and genotype-phenotype correlations.
  • To discuss the implications for disease registries and gene therapy approaches.

Main Methods:

  • Review of recent scientific literature on X-linked immunodeficiencies.
  • Analysis of identified genes and their associated mutations.

Related Experiment Videos

  • Examination of clinical and immunologic data from patients.
  • Assessment of outcomes from gene therapy trials.

    • Main Results:

    • Identification of at least seven genes involved in X-linked immunodeficiencies.
    • Demonstration of strong genotype-phenotype correlations in some XLIDs.
    • Establishment of disease-specific registries for better characterization.
    • Successful gene therapy for X-linked severe combined immune deficiency (XSCID) with observed adverse effects.

    Conclusions:

    • Molecular genetics has significantly advanced the understanding and diagnosis of XLIDs.
    • Gene therapy offers potential for treating XLID, but safety concerns require further investigation.
    • Continued research is essential for refining diagnostic tools and therapeutic strategies for XLIDs.